S
SMMT
Summit Therapeutics Inc. Common Stock
$15.13
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Summit Therapeutics Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$1.12
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.30
Nov 11
Posts
No posts about SMMT yet.
About Summit Therapeutics Inc. Common Stock
Summit Therapeutics is a clinical-stage biopharmaceutical company developing cancer treatments. Its lead drug, ivonescimab, is a single antibody engineered to block two proteins that tumors rely on: PD-1, which cancer cells use to hide from the immune system, and VEGF, which tumors use to grow the blood vessels that feed them. The company has no approved products on the market yet, so it earns no product revenue and instead funds its research through investor capital and partnership deals with larger drugmakers.